Genome & Company announced a private placement of series 1 unsecured privately placed convertible bonds with bearer interest for gross proceeds of KRW 23,000,000,000 on April 5, 2023. The transaction will included participation from IBK Capital Corporation, for KRW 3,000,000,000, NH Investment & Securities Co., Ltd. for KRW 3,000,000,000, KDB Capital Corp. for KRW 3,000,000,000, and other investors.

The bonds will carry 0% coupon rate, 3% yield to maturity rate, will mature on April 7, 2028 and will be 100% convertible into 1,097,328 common shares of the company at a fixed conversion price of KRW 20,960 per share from April 7, 2024 to March 7, 2028. The transaction has been approved by the board of directors of the company. The payment date is on April 7, 2023.

The securities to be issued in the transaction will be subject to a 1 year hold period from date of issuance.